CA2335366A1 - Compositions and methods for treating elevated blood cholesterol - Google Patents
Compositions and methods for treating elevated blood cholesterol Download PDFInfo
- Publication number
- CA2335366A1 CA2335366A1 CA002335366A CA2335366A CA2335366A1 CA 2335366 A1 CA2335366 A1 CA 2335366A1 CA 002335366 A CA002335366 A CA 002335366A CA 2335366 A CA2335366 A CA 2335366A CA 2335366 A1 CA2335366 A1 CA 2335366A1
- Authority
- CA
- Canada
- Prior art keywords
- geranylgeranyl
- geranylgeraniol
- hmg
- coa reductase
- reductase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9052798P | 1998-06-24 | 1998-06-24 | |
US60/090,527 | 1998-06-24 | ||
GBGB9817167.1A GB9817167D0 (en) | 1998-08-06 | 1998-08-06 | Compositions and methods for treating elevated blood cholesterol |
GB9817167.1 | 1998-08-06 | ||
PCT/US1999/013887 WO1999066929A1 (en) | 1998-06-24 | 1999-06-21 | Compositions and methods for treating elevated blood cholesterol |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2335366A1 true CA2335366A1 (en) | 1999-12-29 |
Family
ID=26314174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002335366A Abandoned CA2335366A1 (en) | 1998-06-24 | 1999-06-21 | Compositions and methods for treating elevated blood cholesterol |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1089731A4 (de) |
JP (1) | JP2002518448A (de) |
AU (1) | AU754767B2 (de) |
CA (1) | CA2335366A1 (de) |
WO (1) | WO1999066929A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000071531A1 (en) | 1999-05-24 | 2000-11-30 | America River Nutrition, Inc. | Tocotrienols and geranylgeraniol from bixa orellana byproducts |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
CA2521149C (en) | 2003-04-08 | 2014-03-25 | Barrie Tan | Annatto extract compositions, including geranyl geraniols and methods of use |
WO2010098906A1 (en) * | 2009-02-24 | 2010-09-02 | Madeira Therapeutics | Liquid statin formulations |
US20120171286A1 (en) * | 2009-04-27 | 2012-07-05 | Beth Isreal Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of statin-induced myopathy |
WO2013130654A1 (en) * | 2012-02-29 | 2013-09-06 | Coyote Pharmaceuticals, Inc. | Gga and gga derivatives, compositions thereof and methods for treating neurodegenerative diseases including paralysis including them |
TW201427938A (zh) * | 2012-10-01 | 2014-07-16 | Coyote Pharmaceuticals Inc | 香葉基香葉基丙酮(gga)和其衍生物之製備方法及彼等與脲或硫脲之共結晶作用 |
US9119808B1 (en) | 2012-10-08 | 2015-09-01 | Coyote Pharmaceuticals, Inc. | Treating neurodegenerative diseases with GGA or a derivative thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8105781A1 (es) * | 1979-07-27 | 1981-06-16 | Sankyo Co | Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos. |
US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
CA2044162A1 (fr) * | 1989-10-13 | 1991-04-14 | Jacques Borg | Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophes et cytoprotectrices, et compositions pharmaceutiques les contenant |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5639653A (en) * | 1993-07-19 | 1997-06-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy | Method for proliferating Vγ2Vδ2 T cells |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
IL112639A0 (en) * | 1994-03-11 | 1995-05-26 | Bristol Myers Squibb Co | A pharmaceutical composition containing pravastin |
US5574025A (en) * | 1994-10-26 | 1996-11-12 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
IT1276162B1 (it) * | 1995-11-23 | 1997-10-27 | Baldacci Lab Spa | Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche |
JPH1087480A (ja) * | 1996-09-13 | 1998-04-07 | Eisai Co Ltd | 抗動脈硬化治療剤 |
US5763646A (en) * | 1997-03-13 | 1998-06-09 | Ranbaxy Laboratories, Ltd. | Process for manufacturing simvastatin from lovastatin or mevinolinic acid |
-
1999
- 1999-06-21 EP EP99930451A patent/EP1089731A4/de not_active Withdrawn
- 1999-06-21 WO PCT/US1999/013887 patent/WO1999066929A1/en not_active Application Discontinuation
- 1999-06-21 AU AU46989/99A patent/AU754767B2/en not_active Ceased
- 1999-06-21 CA CA002335366A patent/CA2335366A1/en not_active Abandoned
- 1999-06-21 JP JP2000555615A patent/JP2002518448A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1089731A4 (de) | 2003-06-18 |
AU4698999A (en) | 2000-01-10 |
AU754767B2 (en) | 2002-11-21 |
EP1089731A1 (de) | 2001-04-11 |
JP2002518448A (ja) | 2002-06-25 |
WO1999066929A1 (en) | 1999-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2632967T3 (es) | Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma | |
EP1919466B9 (de) | Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat | |
EP1660066B1 (de) | Pharmazeutische zusammensetzung mit einer kombination aus metformin und einem statin | |
CA2296726C (en) | Combination therapy | |
US11786482B2 (en) | Compositions and methods using a cannabinoid to enhance bioavailability of a statin | |
US20070166321A1 (en) | Compositions and Methods for Reducing Cholesterol and Inflammation | |
AU754767B2 (en) | Compositions and methods for treating elevated blood cholesterol | |
US9642860B2 (en) | Combinations of corroles and statins | |
EP0373507A1 (de) | Zusammensetzung eines HMG-CoA-Reductase-Inhibitors und anderen Serumcholesterol senkenden Mitteln und Verfahren zur Senkung von Serumcholesterol durch diese Zusammensetzung | |
KR101258422B1 (ko) | 신규의 트리글리세리드 저하제 | |
US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
CA2336192A1 (en) | Compositions and methods for treating elevated blood cholesterol | |
US20040023919A1 (en) | Blood lipid ameliorant composition | |
KR101086040B1 (ko) | 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체 | |
Jurkowski | Statins regulate IL-1β-induced RANKL and OPG production by human gingival fibroblasts | |
CA2494801A1 (en) | Medicinal composition containing hmg-coa reductase inhibitor | |
WO2002098353A2 (en) | Compositions and methods for inhibiting bone resorption | |
RU2008144912A (ru) | Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |